PEAK6 Investments’s Intellia Therapeutics NTLA Stock Holding History

PEAK6 Investments’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$617K	Sell	30,000 -22,500	-43%	-$519K	﹤0.01%	2202
2024 Q2	$1.17M	Buy	52,500 +30,000	+133%	+$714K	﹤0.01%	1710
2024 Q1	$619K	Sell	22,500 -1,500	-6%	-$41.7K	﹤0.01%	2291
2023 Q4	$732K	Buy	+24,000	New	+$690K	﹤0.01%	2334
2022 Q2	–	Sell	-22,200	Closed	-$1.61M	–	6371
2022 Q1	$1.61M	Buy	22,200 +12,600	+131%	+$1.07M	﹤0.01%	2056
2021 Q4	$1.14M	Buy	+9,600	New	+$1.2M	﹤0.01%	2453

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Investments's NTLA Position: Q3 2024 in Review

PEAK6 Investments sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 3,143 shares — an estimated $72.5K sold.

PEAK6 Investments first reported a position in NTLA in Q2 2021 and held it in 4 quarters. The position peaked at $372K in Q1 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

PEAK6 Investments reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
PEAK6 Investments sold 3,143 Intellia Therapeutics shares in Q3 2024, an estimated $72.5K.
PEAK6 Investments first reported a position in Intellia Therapeutics in Q2 2021 and held it in 4 quarters.
PEAK6 Investments's Intellia Therapeutics position peaked at $372K in Q1 2024.
283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.